LY2780301, a p70S6K/AKT Inhibitor, in Combination With Weekly Paclitaxel in HER2-Negative Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients
Eur. J. Cancer 2021 Nov 12;159(xx)205-214, C Vicier, P Sfumato, N Isambert, F Dalenc, M Robert, C Levy, K Rezai, M Provansal, J Adélaïde, S Garnier, A Guille, N Carbuccia, C Popovici, E Charafe-Jauffret, M Chaffanet, D Birnbaum, J Pakradouni, F Bertucci, JM Boher, R Sabatier, A GonçalvesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.